SIC
ALLO icon

SJS Investment Consulting’s Allogene Therapeutics ALLO Stock Holding History

SJS Investment Consulting’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$955 Buy
459
+411
+856% +$903 ﹤0.01% 2045
2026
Q1 		$118 Buy
48
+40
+500% +$80 ﹤0.01% 2107
2025
Q4 		$11 Buy
+8
New +$11 ﹤0.01% 2079
2023
Q1 		– Sell
-5
Closed -$31 – 1582
2022
Q4 		$31 Buy
5
+2
+67% +$19 ﹤0.01% 1563
2022
Q3 		$0 Buy
+3
New +$41 ﹤0.01% 1013

Other funds holding ALLO

WCM
Wildcat Capital Management New York $229M AUM 132.65% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
AA
ALPS Advisors Denver, Colorado $21.3B AUM 23.41% 1-Year Est. Return
HDA
Harold Davidson & Associates Los Angeles, California $231M AUM 35.6% 1-Year Est. Return
PFSRSONJ
Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
CWMS
CFG Wealth Management Services Indianapolis, Indiana $107M AUM
CUAMC
China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return
NL
Navalign LLC Encino, California $429M AUM 18.12% 1-Year Est. Return

SJS Investment Consulting's ALLO Position: Q2 2026 in Review

SJS Investment Consulting increased its Allogene Therapeutics (ALLO) stake by 856% in Q2 2026, buying an estimated $903 and bringing the position to 459 shares worth $955. The position accounts for ﹤0.01% of the portfolio, ranked #2045.

SJS Investment Consulting first reported a position in ALLO in Q3 2022 and has held it in 5 quarters since. 34 funds tracked by Wall St. Rank hold ALLO as of Q2 2026.

  • SJS Investment Consulting held 459 shares of Allogene Therapeutics worth $955 as of Q2 2026.
  • SJS Investment Consulting bought 411 Allogene Therapeutics shares in Q2 2026, an estimated $903.
  • Allogene Therapeutics made up ﹤0.01% of SJS Investment Consulting's portfolio in Q2 2026, its #2045 holding.
  • SJS Investment Consulting first reported a position in Allogene Therapeutics in Q3 2022 and has held it in 5 quarters since.
  • 34 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2026.

Based on SJS Investment Consulting's 13F filing for Q2 2026, filed 22 Jul 2026.